Abbott Laboratories $ABT Shares Acquired by Blair William & Co. IL

Key Points

• Blair William & Co. IL increased its holdings in Abbott Laboratories (ABT) by 1.5%, owning 1,603,305 shares valued at approximately $218 million after acquiring additional shares in the 2nd quarter.
• Numerous institutional investors recently adjusted their stakes in Abbott, with 75.18% of the stock owned by these entities, indicating strong institutional support.
• Abbott announced a quarterly dividend of $0.59 per share, with an annual yield of 1.8%, set to be paid on November 17 to shareholders on record as of October 15.

Blair William & Co. IL lifted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,603,305 shares of the healthcare product maker's stock after acquiring an additional 24,281 shares during the period. Blair William & Co. IL owned 0.09% of Abbott Laboratories worth $218,065,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its stake in Abbott Laboratories by 8.4% in the first quarter. Wealthcare Advisory Partners LLC now owns 13,282 shares of the healthcare product maker's stock valued at $1,762,000 after acquiring an additional 1,024 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Abbott Laboratories by 17.0% during the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker's stock worth $5,103,000 after purchasing an additional 5,590 shares during the last quarter. Simplicity Wealth LLC increased its position in shares of Abbott Laboratories by 115.2% during the first quarter. Simplicity Wealth LLC now owns 17,758 shares of the healthcare product maker's stock worth $2,356,000 after purchasing an additional 9,506 shares in the last quarter. Finally, Fiduciary Financial Group LLC lifted its holdings in shares of Abbott Laboratories by 15.1% in the 1st quarter. Fiduciary Financial Group LLC now owns 3,289 shares of the healthcare product maker's stock valued at $409,000 after purchasing an additional 431 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on the company. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 target price on the stock. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Weiss Ratings reissued a "buy (b)" rating on shares of Abbott Laboratories in a research report on Wednesday. Finally, Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and increased their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $146.24.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $134.45 on Thursday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a 50 day simple moving average of $132.30 and a 200-day simple moving average of $131.48. The company has a market cap of $234.00 billion, a price-to-earnings ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.